01/20/2022 | Press release | Distributed by Public on 01/20/2022 15:07
SAN FRANCISCO--(BUSINESS WIRE)--Jan. 20, 2022--
Better Therapeutics, Inc. ("Better Therapeutics"; NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today announced that Kevin Appelbaum, Chief Executive Officer, is scheduled to participate in two upcoming investor events as follows:
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics' PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines. For more information visit: bettertx.com
BTTX-PR
View source version on businesswire.com: https://www.businesswire.com/news/home/20220120005817/en/
Investor Relations:
Mark Heinen
[email protected]
Media:
Cassidy McClain
[email protected]
619.849.6009
Source: Better Therapeutics, Inc.